CellSource Co

CellSource Co Depreciation & Amortization

The Depreciation & Amortization of CellSource Co (4880.T) as of Oct 28, 2026 is 54.98 M JPY. In the previous year, Depreciation & Amortization was 25.48 M JPY — a change of 115.78% (higher).

Depreciation & Amortization

54.98 MJPY

YoY

115.78%

Last updated:

Depreciation & Amortization of CellSource Co is 2024 54.98 M JPY. Depreciation & Amortization of CellSource Co was 2023 25.48 M JPY. It decreases by 115.78% higher compared to the previous year.

The CellSource Co Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2017
177,000.00 JPY
Jan 1, 2018
2.82 M JPY
Jan 1, 2019
6.73 M JPY
Jan 1, 2020
8.02 M JPY
Jan 1, 2021
12.20 M JPY
Jan 1, 2022
13.13 M JPY
Jan 1, 2023
25.48 M JPY
Jan 1, 2024
54.98 M JPY
The CellSource Co Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
54.98 MJPY+115.78%
25.48 MJPY+94.07%
13.13 MJPY+7.59%
12.20 MJPY+52.14%
8.02 MJPY+19.11%
6.73 MJPY+138.88%
2.82 MJPY+1,492.66%
177,000.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Depreciation & Amortization of CellSource Co is 54.98 M JPY in 2024.

Depreciation & Amortization of CellSource Co changed from 25.48 M JPY to 54.98 M JPY, representing a 115.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co